Lomustine

Alkylating Drug — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Lomustine is an ofp drug in the Alkylating Drug class catalogued in DrugCentral. It was first approved by the FDA in 1976. Its mechanism of action is classified as Alkylating Activity. Recorded indications include Hodgkin's disease and Neoplasm of brain.

• Approval status: ofp (first approved 1976 by the FDA).
• Drug class: Alkylating Drug.
• Mechanism of action: Alkylating Activity.
• Indications: Hodgkin's disease and Neoplasm of brain.
• ATC code: L01AD02 (Nitrosoureas).
• Molecular formula: C9H16ClN3O2; molecular weight 233.70 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Hodgkin's disease
• Neoplasm of brain

Off-label uses (1)

• Allogeneic bone marrow transplantation

Contraindications (15)

• Bacterial infectious disease
• Bleeding
• Bone marrow depression
• Breastfeeding (mother)
• Drug-induced hepatitis
• Fibrosis of lung
• Hyperbilirubinemia
• Kidney disease
• Leukopenia
• Liver function tests abnormal
• Mycosis
• Pregnancy, function
• Pulmonary Infiltrates
• Thrombocytopenic disorder
• Viral disease

Mechanism & targets

• Mechanism of action (MoA): Alkylating Activity
• Established pharmacologic class: Alkylating Drug

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1976-08-04	FDA	—	CORDEN PHARMA

ATC classification

ATC code	Therapeutic hierarchy
L01AD02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Nitrosoureas

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Thrombocytopenia	225.4
Disease progression	154.2
Neutropenia	132.1
Death	120.0
Eastern Cooperative Oncology Group performance status worsened	117.5
Tumour pseudoprogression	106.3
Platelet count decreased	102.2
Seizure	96.8
Second primary malignancy	82.9
Off label use	80.7
Neoplasm progression	70.8
Nausea	67.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Lomustine is on its molecule page.

• Molecular formula: C₉H₁₆ClN₃O₂
• Molecular weight: 233.70 g/mol
• CAS number: —
• InChIKey: GQYIWUVLTXOXAJ-UHFFFAOYSA-N
• PubChem CID: 3950

ClCCN(N=O)C(=O)NC1CCCCC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lomustine used for?

DrugCentral lists the following indications for Lomustine: Hodgkin's disease and Neoplasm of brain.

How does Lomustine work?

Lomustine is classified as Alkylating Activity.

When was Lomustine first approved?

Lomustine was first approved by the FDA in 1976.

What drug class does Lomustine belong to?

Lomustine is in the Alkylating Drug class.

What is the chemical formula of Lomustine?

Lomustine has the molecular formula C9H16ClN3O2 and a molecular weight of 233.70 g/mol.

Sources

• DrugCentral drug card 1596 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL514 — compound record and bioactivity
• PubChem CID 3950 — chemical identifiers
• DrugBank DB01206 — drug record
• FDA UNII 7BRF0Z81KG — substance identity
• DailyMed: FDA labels for Lomustine — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.